TIDAL: Target-Induced Droplet Assembly of Ligands
Special Notice from Department of Energy.
Data as of Oct 24, 2026. Sources: SAM.gov and Grants.gov. Snapshot govcon-directory-20261024T104923Z-2151694.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services. Counts and totals are computed by DSE from public SAM.gov and Grants.gov notices. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Closing in 46 days
Notice details
- Agency
- Department of Energy
- Sub-tier agency
- ENERGY, DEPARTMENT OF
- Notice type
- Special Notice
- Solicitation number
- S-197478
- Product/service code
- AJ11
- Place of performance
- Los Alamos, New Mexico
- Posted
- Sep 9, 2026
- Response deadline
- Dec 9, 2026
- Source
- SAM.gov
Description
Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) transforms the small antibody fragments known as nanobodies into a programmable, protein-only material that organizes itself on demand. By harnessing a natural process called liquid-liquid phase separation, TIDAL lets these binders gather into dense, dynamic droplets precisely when they encounter their intended target, giving developers a single platform that can purify proteins without costly resins, deliver drugs as a self-forming slow-release depot and even trap harmful proteins inside living cells. The outcome is a versatile toolkit that lowers production costs, simplifies manufacturing and opens fresh therapeutic and diagnostic possibilities, all from a building block that biology already knows how to make. Overview At the heart of TIDAL is a small, engineered tag, called an encapsulation peptide (EP), that is fused to a nanobody. When many of these tagged nanobodies are present, they undergo liquid-liquid phase separation, similar to what makes oil bead up in water, and they collect into concentrated liquid droplets made entirely of protein. Binding to the target molecule intensifies the effect, so the droplets form most strongly exactly where and when that target is present. Because the assembly is dynamic and reversible, the droplets behave as stimuli-responsive materials whose thickness and flow can be tuned by the target ligand, allowing one design to serve as a
Summarized from the official notice. The description is shortened; read the full text on the official notice.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Similar open notices
- TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterClosing in 53 days
- TECHNOLOGY LICENSING OPPORTUNITY: NanoFETClosing in 55 days
- TECHNOLOGY LICENSING OPPORTUNITY: Protein-Based Rare Earth Recovery via CondensationClosing in 60 days
- TECHNOLOGY LICENSING OPPORTUNITY: SignalGenClosing in 149 days
Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →Frequently asked questions
When is the response deadline?
The published deadline is Dec 9, 2026. That is 46 days after the data date.
What NAICS code applies?
NAICS 541714, Research and Development in Biotechnology (except Nanobiotechnology).
Which agency issued this notice?
Department of Energy.
Where is the official notice?
The link under Official notice opens the source listing.